Xalt2 study (NSCLC/ALK+)

[KatieB 346]

 

 

If you have non-small cell lung cancer (NSCLC) that is ALK positive, you may be interested in learning more about a clinical research study opportunity.

 

The Xalt2 study is being done to find out if an investigational medication is safe and how tumors respond to it in patients with NSCLC whose tumors test positive for the ALK gene.

 

You may be able to join the Xalt2 clinical research study if you:

 

·         Are 18 years of age or older

·         Have been diagnosed with ALK positive NSCLC

Study participants will receive the investigational medication in cycles of approximately 28 days each. Not all participants will be in the study for the same amount of time.

 

To learn more: www.MyXalt2Study.com